GlassScriptPhysician profile
Brian H Sarter
NPI 1851323745
$3,410.91
in general payments reported to CMS, 2019-2025
19 companies · $270 in 2025
The $270 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $231 · 2021: $333 · 2022: $794 · 2023: $1,003 · 2024: $199 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751 · Travel and Lodging: $721 · Education: $0.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $750.80 |
| Travel and Lodging | $720.56 |
| Education | $0.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,492.01 | 2019-2025 | Aveir, Amplatzer Amulet |
| Boston Scientific Corporation | $827.35 | 2019-2025 | Emblem Mri S-Icd, Watchman Flx, General - Therapies |
| Impulse Dynamics (USA) INC. | $335.70 | 2022-2025 | Optimizer |
| Medtronic, INC. | $191.50 | 2021-2025 | Selectsite, Mycarelink, Capsurefix Novus Mri Surescan |
| Medtronic Vascular, INC. | $97.47 | 2020 | |
| Novartis Pharmaceuticals Corporation | $70.58 | 2019-2022 | |
| Amarin Pharma, INC. | $63.12 | 2019-2021 | |
| Pfizer INC. | $48.13 | 2019 | |
| Biosense Webster, INC. | $39.60 | 2024 | Carto 3 |
| E.R. Squibb & Sons, L.L.C. | $38.86 | 2019-2023 | Eliquis |
| Sanofi-Aventis U.S. LLC | $33.52 | 2019 | |
| Amgen INC. | $33.09 | 2019 | |
| Janssen Pharmaceuticals, INC | $30.52 | 2019-2021 | |
| Akcea Therapeutics, INC. | $24.82 | 2019 | |
| Kestra Medical Technology Services, INC. | $24.52 | 2025 | Assure Wcd |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $20.11 | 2019 | |
| Gilead Sciences, INC. | $14.87 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.43 | 2019 | |
| Daiichi Sankyo INC. | $10.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Sarter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.